留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

器官移植受者免疫状态监测最新进展

马军,  贺强,  李先亮

downloadPDF
文章导航 > 器官移植  > 2019 >  10(3): 333-335, 338
马军, 贺强, 李先亮. 器官移植受者免疫状态监测最新进展[J]. 器官移植, 2019, 10(3): 333-335, 338. doi: 10.3969/j.issn.1674-7445.2019.03.019
引用本文: 马军, 贺强, 李先亮. 器官移植受者免疫状态监测最新进展[J]. 器官移植, 2019, 10(3): 333-335, 338. doi: 10.3969/j.issn.1674-7445.2019.03.019
shu
Ma Jun, He Qiang, Li Xianliang. The latest progress on monitoring the immune status of organ transplant recipients[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 333-335, 338. doi: 10.3969/j.issn.1674-7445.2019.03.019
Citation: Ma Jun, He Qiang, Li Xianliang. The latest progress on monitoring the immune status of organ transplant recipients[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 333-335, 338. doi: 10.3969/j.issn.1674-7445.2019.03.019
shu

器官移植受者免疫状态监测最新进展

doi: 10.3969/j.issn.1674-7445.2019.03.019

  • 100020 北京，首都医科大学附属北京朝阳医院肝胆胰脾外科

基金项目: 

国家自然科学基金 81273270

国家自然科学基金 81471590

国家自然科学基金 81571554

详细信息
    作者简介:

    马军，男，1979年生，博士研究生，主治医师，研究方向为肝移植与肝胆胰恶性肿瘤，Email：bobma1979@sina.com

    通讯作者:

    贺强，男，1964年生，博士，主任医师，研究方向为肝移植与肝胆胰恶性肿瘤，Email：heqiang349@sina.com

    李先亮，男，1971年生，博士，副主任医师，研究方向为肝移植与肝胆胰恶性肿瘤，Email：lixianliangbjcy@126.com

  • 中图分类号: R617, R392.4

The latest progress on monitoring the immune status of organ transplant recipients

    摘要
  • 摘要: 器官移植受者术后常规使用免疫抑制剂治疗，如何选择合理的免疫抑制方案，既能避免免疫抑制不足引起的移植物排斥反应，又可减少因免疫过度导致的感染、药物中毒和恶性肿瘤是器官移植术后治疗的一大难题。由于目前没有一种快速有效的方法评估受者的免疫状态，因而无法快速准确地判断免疫抑制方案的使用是否合理。本文从血药浓度监测和免疫状态评估两方面综述了国内外对器官移植术后受者免疫监测应用的最新研究进展，为实体器官移植后免疫监测提供另一种全新思路和选择。

     

    • HTML全文
    • 参考文献(30)
  • [1] 毛家玺, 邹游, 郭闻渊.肝移植治疗肝豆状核变性的效果观察[J].临床肝胆病杂志, 2017, 33(10):1977-1980.DOI: 10.3969/j.issn.1001-5256.2017.10.026.

    MAO JX, ZOU Y, GUO WY. Clinical effect of liver transplantation in the treatment of hepatolenticular degeneration[J]. J Clin Hepatol, 2017, 33(10):1977-1980. DOI: 10.3969/j.issn.1001-5256.2017.10.026.
    [2] SINGH A, GOVIL D, BAVEJA UK, et al. Epidemiological analysis of extended-spectrum beta-lactamase-producing bacterial infections in adult live donor liver transplant patients[J]. Indian J Crit Care Med, 2018, 22(4):290-296. DOI: 10.4103/ijccm.IJCCM_206_17.
    [3] FISHMAN JA. Opportunistic infections--coming to the limits ofimmunosuppression?[J]. Cold Spring Harb Perspect Med, 2013, 3(10):a015669. DOI: 10.1101/cshperspect.a015669.
    [4] KOTARSKA K, WUNSCH E, KEMPIŃSKA-PODHORODECKA A, et al. Factors affecting health-related quality of life and physical activity after liver transplantation for autoimmune and nonautoimmune liver diseases: a prospective, single centre study[J]. J Immunol Res, 2014:738297. DOI: 10.1155/2014/738297.
    [5] GOLDSCHMIDT I, KARCH A, MIKOLAJCZYK R, et al. Immune monitoring after pediatric liver transplantation - the prospective ChilSFree cohort study[J]. BMC Gastroenterol, 2018, 18(1):63. DOI: 10.1186/s12876-018-0795-x.
    [6] 王啸晨, 葛军, 陈雅文, 等.器官移植术后病原体感染检测研究进展[J].器官移植, 2018, 9(6):474-477. DOI: 10.3969/j.issn.1674-7445.2018.06.015.

    WANG XC, GE J, CHEN YW, et al. Research progress on pathogen infection detection after organ transplantation[J]. Organ Transplant, 2018, 9(6):474-477. DOI: 10.3969/j.issn.1674-7445.2018.06.015.
    [7] ADAM R, KARAM V, DELVART V, et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry[J]. Am J Transplant, 2015, 15(5):1267-1282. DOI: 10.1111/ajt.13171.
    [8] GASTACA M, VALDIVIESO A, BUSTAMANTE J, et al. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: results of a single-center cohort[J]. Liver Transpl, 2016, 22(10):1391-1400. DOI: 10.1002/lt.24514.
    [9] KIM JM, KWON CH, JOH JW, et al. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: a randomized prospective study[J]. Liver Transpl, 2016, 22(2):209-216. DOI: 10.1002/lt.24336.
    [10] 王振璞, 蒋欣, 苗书斋, 等.甲泼尼龙与醋酸泼尼松治疗肾移植术后肺部感染[J].实用医学杂志, 2017, 33(1):22-26.DOI: 10.3969/j.issn.1006-5725.2017.01.006.

    WANG ZP, JIANG X, MIAO SZ, et al. Prospective study of methylprednisolone and prednisone therapy for patients with pulmonary infection after renal transplantation[J]. J Pract Med, 2017, 33(1):22-26. DOI: 10.3969/j.issn.1006-5725.2017.01.006.
    [11] MORENO GONZALES M, MYHRE L, TANER T. Sublingual tacrolimus in liver transplantation: a valid option?[J]. Transplant Proc, 2016, 48(6):2102-2106. DOI: 10.1016/j.transproceed.2016.03.043.
    [12] HURST AL, CLARK N, CARPENTER TC, et al. Supra-therapeutic tacrolimus concentrations associated with concomitant nicardipine in pediatric liver transplant recipients[J]. Pediatr Transplant, 2015, 19(4):E83-E87. DOI: 10.1111/petr.12470.
    [13] STRATHIE PAGE SJ, TAIT CP. Mycophenolic acid in dermatology a century after its discovery[J]. Australas J Dermatol, 2015, 56(1):77-83. DOI: 10.1111/ajd.12259.
    [14] DURAND M, LACOSTE P, DANGER R, et al. High circulating CD4+CD25hiFOXP3+ T-cell sub-population early after lung transplantation is associated with development of bronchiolitis obliterans syndrome[J]. J Heart Lung Transplant, 2018, 37(6):770-781. DOI: 10.1016/j.healun.2018.01.1306.
    [15] 陈规划, 姜楠.肝移植免疫耐受的研究热点和思考[J].器官移植, 2017, 8(1):1-4. DOI: 10.3969/j.issn.1674-7445.2017.01.001.

    CHEN GH, JIANG N. Research focus and thinking of immune tolerance in liver transplantation[J]. Organ Transplant, 2017, 8(1):1-4. DOI: 10.3969/j.issn.1674-7445.2017.01.001.
    [16] SUGIYAMA K, TSUKAGUCHI M, TOYAMA A, et al. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor[J]. Exp Clin Transplant, 2014, 12(3):195-199. http://www.ncbi.nlm.nih.gov/pubmed/24907718
    [17] 邓小红, 张倩倩, 蔡燕, 等.肝癌患者肝移植前外周血免疫表型分析[J].中山大学学报(医学科学版), 2018, 39(2):178-185, 226. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201802003

    DENG XH, ZHANG QQ, CAI Y, et al. Detection of immune cell subsets of peripheral blood in hepatocellular carcinoma before liver transplantation[J]. J Sun Yat-sen Univ(Med Sci), 2018, 39(2):178-185, 226. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201802003
    [18] MUNN DH, MELLOR AL. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses[J]. Trends Immunol, 2013, 34(3):137-143. DOI: 10.1016/j.it.2012.10.001.
    [19] PÉREZ-JACOISTE ASÍN MA, FERNÁNDEZ-RUIZ M, LÓPEZ-MEDRANO F, et al. Monitoring of intracellular adenosine triphosphate in CD4(+) T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients[J]. Transpl Int, 2016, 29(10):1094-1105. DOI: 10.1111/tri.12816.
    [20] LIU F, XU L, SHENG C, et al. Optimization and application of an HPLC method for quantification of inosine-5'-monophosphate dehydrogenase activity as a pharmacodynamic biomarker of mycophenolic acid in Chinese renal transplant patients[J]. Clin Chim Acta, 2018, 485:333-339. DOI: 10.1016/j.cca.2018.06.042.
    [21] KARAKHANOVA S, OWEIRA H, STEINMEYER B, et al. Interferon-γ, interleukin-10 and interferon-inducible protein 10 (CXCL10) as serum biomarkers for the early allograft dysfunction after liver transplantation[J]. Transpl Immunol, 2016, 34:14-24. DOI: 10.1016/j.trim.2015.12.001.K
    [22] CHAE MS, KIM JW, CHUNG HS, et al. The impact of serum cytokines in the development of early allograft dysfunction in living donor liver transplantation[J].Medicine (Baltimore), 2018, 97(16):e0400. DOI: 10.1097/MD.0000000000010400.
    [23] KREBS K, BÖTTINGER N, HUANG LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice[J]. Gastroenterology, 2013, 145(2):456-465. DOI: 10.1053/j.gastro.2013.04.047.
    [24] SHEN ZY, ZHENG WP, LIU T, et al. Effects of dendritic cells from hepatitis B virus transgenic mice-stimulated autologous lymphocytes on hepatitis B virus replication: a study on the impact of specific sensitized effector cells on in vitro virus replication[J]. Viral Immunol, 2015, 28(2):85-92. DOI: 10.1089/vim.2014.0053.
    [25] RAZONABLE RR, HUMAR A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4): 93-106. DOI: 10.1111/ajt.12103.
    [26] KEMPF W. Cutaneous CD30-positive lymphoproliferative disorders[J]. Surg Pathol Clin, 2014, 7(2):203-228. DOI: 10.1016/j.path.2014.02.001.
    [27] 于涛, 陈文, 刘志佳, 等.常用免疫抑制剂对Tfr细胞和Breg细胞的作用研究[J].器官移植, 2018, 9(5):360-364, 404.DOI: 10.3969/j.issn.1674-7445.2018.05.007.

    YU T, CHEN W, LIU ZJ, et al. Effect of common immunosuppressants on Tfr cells and Breg cells[J].Organ Transplant, 2018, 9(5):360-364, 404. DOI: 10.3969/j.issn.1674-7445.2018.05.007.
    [28] 臧超然, 张永宏.免疫抑制性细胞在肝细胞癌发生发展中的作用[J].临床肝胆病杂志, 2018, 34(7):1560-1564.DOI: 10.3969/j.issn.1001-5256.2018.07.042.

    ZANG CR, ZHANG YH. Role of immunosuppressive cells in the development and progression of hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34(7):1560-1564. DOI: 10.3969/j.issn.1001-5256.2018.07.042.
    [29] FERNÁNDEZ-RAMOS AA, POINDESSOUS V, MARCHETTI-LAURENT C, et al. The effect of immunosuppressive molecules on T-cell metabolic reprogramming[J]. Biochimie, 2016, 127:23-36. DOI: 10.1016/j.biochi.2016.04.016.
    [30] DOCHERTY MH, O'SULLIVAN ED, BONVENTRE JV, et al. Cellular senescence in the kidney[J]. J Am Soc Nephrol, 2019, 30(5):726-736. DOI: 10.1681/ASN.2018121251.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  187
  • HTML全文浏览量:  35
  • PDF下载量:  52
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-05-15

目录

    /

    返回文章
    返回

    《器官移植》微信订阅号

    《器官移植》微信服务号

    联系我们
    • 电话: 020-38736410
    • Email: organtranspl@163.com
    • 地址: 广州市天河区天河路600号中山大学附属第三医院（广州）期刊有限责任公司
    • 《器官移植》编辑部  粤ICP备2021030844号
    友情链接

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计